Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Croom KF, Perry CM, Plosker GL.

CNS Drugs. 2009;23(5):427-52. doi: 10.2165/00023210-200923050-00006. Review.

PMID:
19453203
2.

Mirtazapine: a review of its use in major depression.

Holm KJ, Markham A.

Drugs. 1999 Apr;57(4):607-31. Review.

PMID:
10235695
3.

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.

Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH.

Int Clin Psychopharmacol. 2010 Jul;25(4):189-98. doi: 10.1097/YIC.0b013e328330adb2.

PMID:
20531012
4.

A risk-benefit assessment of mirtazapine in the treatment of depression.

Kasper S, Praschak-Rieder N, Tauscher J, Wolf R.

Drug Saf. 1997 Oct;17(4):251-64. Review. Erratum in: Drug Saf 1998 Feb;18(2):123.

PMID:
9352961
5.

Mirtazapine: other indications.

Falkai P.

J Clin Psychiatry. 1999;60 Suppl 17:36-40; discussion 46-8. Review.

6.

Mirtazapine. A pharmacoeconomic review of its use in depression.

Holm KJ, Jarvis B, Foster RH.

Pharmacoeconomics. 2000 May;17(5):515-34. Review.

PMID:
10977391
7.

Care of depressed patients with anxiety symptoms.

Nutt DJ.

J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. Review.

8.
10.

A review of the pharmacological and clinical profile of mirtazapine.

Anttila SA, Leinonen EV.

CNS Drug Rev. 2001 Fall;7(3):249-64. Review.

11.

Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group.

J Clin Psychiatry. 2008 Sep;69(9):1404-15. Review.

PMID:
19193341
12.
13.

Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.

Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N.

Support Care Cancer. 2008 Nov;16(11):1291-8. doi: 10.1007/s00520-008-0425-1. Epub 2008 Feb 26.

PMID:
18299900
14.

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.

Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ; Comparative Efficacy Antidepressants Study Group.

CNS Drugs. 2005;19(2):137-46.

PMID:
15697327
15.

Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.

Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):175-84.

PMID:
15319015
16.

Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.

Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, Sunada N, Onohara A, Hatashita Y, Serretti A, Kinoshita T.

J Psychiatr Res. 2017 Jun;89:97-104. doi: 10.1016/j.jpsychires.2017.02.003. Epub 2017 Feb 3.

PMID:
28213170
17.

Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.

Nutt DJ.

Depress Anxiety. 1998;7 Suppl 1:7-10. Review.

PMID:
9597345
18.

Mirtazapine versus other antidepressive agents for depression.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Review.

19.

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.

Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, van der Vegte-Senden M, Baker RA, Simmons JH, Schutte AJ.

J Clin Psychopharmacol. 2006 Feb;26(1):75-8.

PMID:
16415711
20.

A pilot study of mirtazapine in post-traumatic stress disorder.

Connor KM, Davidson JR, Weisler RH, Ahearn E.

Int Clin Psychopharmacol. 1999 Jan;14(1):29-31.

PMID:
10221639

Supplemental Content

Support Center